Evidence map›Paper›PMID 31879786›Full record

ArticleThe Journal of nutrition2020

Pretreatment with Yeast-Derived Complex Dietary Polysaccharides Suppresses Gut Inflammation, Alters the Microbiota Composition, and Increases Immune Regulatory Short-Chain Fatty Acid Production in C57BL/6 Mice.

Radhika Gudi, Jada Suber, Robert Brown, Benjamin M Johnson, Chenthamarakshan Vasu

Open access · greenAbstract read
In one paragraph

Article in The Journal of nutrition, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Frontiers in immunology · 2025
    Review
  7. Nutrients · 2024
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Inflammatory Bowel Diseases and Gut Microbiota.International journal of molecular sciences · 2023
    Review
  13. Fecal microbiota transplantation fromFrontiers in microbiology · 2023
    Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Radhika GudiDepartment of Microbiology and Immunology, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.
Jada SuberDepartment of Microbiology and Immunology, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.
Robert BrownDepartment of Microbiology and Immunology, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.
Benjamin M JohnsonDepartment of Microbiology and Immunology, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.
Chenthamarakshan VasuDepartment of Microbiology and Immunology, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.
Medical University of South Carolina · US

Funding

MUSC Post-Baccalaureate Research Education ProgramR25GM113278 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DELEON-PENNELL, KRISTINE Y, PENROD-MARTIN, RACHEL · 2015 to 2024
$2.7M
Contribution of Gut Symbiotic Bacteria to AutoimmunityR21AI133798 · NIAID · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI VASU, CHENTHAMARAKSHAN · 2017 to 2018
$561k
Contribution of X-linked TLR-Gut microbiota interaction to Juvenile Onset of Systemic AutoimmunityR21AI136339 · NIAID · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI VASU, CHENTHAMARAKSHAN · 2018 to 2019
$561k
NIAID NIH HHS R21 AI133798NIAID NIH HHS R21 AI136339NIGMS NIH HHS R25 GM113278
6 · The paper itself

Abstract

backgroundβ-Glucans (BGs), a group of complex dietary polysaccharides (CDPs), are available as dietary supplements. However, the effects of orally administered highly purified BGs on gut inflammation are largely unknown.

objectivesThe aim of this study was to investigate the impact of orally administering highly purified, yeast-derived BG (YBG; β-1,3/1,6-d-glucan) on susceptibility to colitis.

methodsEight-week-old C57BL/6 (B6) mice were used in a series of experiments. Experiment (Expt) 1: male and female mice were treated every day, for 40 d, with saline (control) or 250 μg YBG, followed by 2.5% (wt:vol) dextran sulfate sodium (DSS) in drinking water during days 30-35; and colitis severity and intestinal immune phenotype were determined. Expt 2: female B6 mice were treated with saline or YBG for 30 d and intestinal immune phenotype, gut microbiota composition, and fecal SCFA concentrations were determined. Expt 3: female B6 mice were treated as in Expt 2, given drinking water with or without antibiotics [Abx; ampicillin (1 g/L), vancomycin (0.5 g/L), neomycin (1 g/L), and metronidazole (1 g/L)] during days 16-30, and gut immune phenotype and fecal SCFA concentrations were determined. Expt 4: female B6 Foxp3-green fluorescent protein (-GFP) reporter mice were treated as in Expt 3, and intestinal T-regulatory cell (Treg) frequencies and immune phenotypes were determined. Expt 5: female mice were treated as in Expt 1, given drinking water with or without antibiotics during days 16-40, and colitis severity and intestinal cytokine production were determined.

resultsCompared with controls, the YBG group in Expt 1 exhibited suppressive effects on features of colitis, such as loss of body weight (by 47%; P < 0.001), shortening of colon (by 24%; P = 0.016), and histopathology severity score (by 45%; P = 0.01). The YBG group of Expt 2 showed a shift in the abundance of gut microbiota towards Bacteroides (by 16%; P = 0.049) and Verrucomicrobia (mean ± SD: control = 7.8 ± 0.44 vs. YBG = 21.0 ± 9.6%) and a reduction in Firmicutes (by 66%; P < 0.001). The YBG group also showed significantly higher concentrations of fecal SCFAs such as acetic (by 37%; P = 0.016), propionic (by 47%; P = 0.026), and butyric (by 57%; P = 0.013) acids. Compared with controls, the YBG group of Expt 2 showed higher frequencies of Tregs (by 32%; P = 0.043) in the gut mucosa. Depletion of gut microbiota in the YBG group of mice caused diminished fecal SCFA concentrations (Expt 3) and intestinal Treg frequencies (Expt 4). Compared with the YBG group, the YBG-(Abx) group of Expt 5 showed aggravated colitis features including loss of body weight (by >100%; P < 0.01) and colonic inflammation score (by 42%; P = 0.04).

conclusionsStudies using B6 mice show that dietary BGs are beneficial for promoting intestinal health when the gut microbiota is intact. However, these CDPs may produce adverse effects if gut microbiota is compromised.

Indexed as

Animalsbeta-GlucansColitisDextran SulfateFatty Acids, VolatileFecesFemaleForkhead Transcription FactorsGastrointestinal MicrobiomeGene Knock-In TechniquesGreen Fluorescent ProteinsImmunityIntestinesMaleMiceMice, Inbred C57BLbeta-GlucansDextran SulfateFatty Acids, VolatileForkhead Transcription FactorsFoxp3 protein, mouseGreen Fluorescent ProteinsPolysaccharidescolitisgut inflammationgut microbiotagut mucosaimmune modulationimmune regulationshort-chain fatty acidyeast β-glucan

Identifiers

PMID31879786
PMCPMC7198290
OpenAlexW2998721503

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.